Clinical Trial Update: 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating 68Ga-PSMA PET/CT or PET/MRI in patients with recurrent prostate cancer has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-PSMA PET/CT (68Ga-PSMA PET/CT imaging agent)

Snippet

Sponsor: Stanford University | Conditions: Recurrent Prostate Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-03-14